アストラゼネカ

 AZNのチャート


 AZNの企業情報

symbol AZN
会社名 AstraZeneca Plc (アストラゼネカ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 アストラゼネカ(AstraZeneca PLC)はグローバルな生物医薬会社である。同社は心臓血管、胃腸、感染症、神経科学、腫瘍学及び呼吸・炎症の6つ健康分野向けに処方薬の発見・開発及び商業化を行う。同社は抗生剤などの病気治療薬、酸関連疾患治療用の「Merrem/Meronem」及び「Losec/Prilosec」を含む各種薬剤を提供する。同社商品には「Crestor」、「Atacand」、「Seloken/Toprol-XL」、「Plendil」、「Onglyza」、「Zestril」、「Symbicort」及び「Zoladex」等がある。同社は世界中で複数の研究開発(R&D)施設、生産販売施設を保有・運営する。同社は中国メキシコブラジル及びロシア等100以上の国で事業を展開している。平成23年8月31日、同社はDENTSPLY International IncへのAstra Tech事業の売却を完了した。  アストラゼネカはイギリスの大手製薬企業。循環器、消化器、感染症、神経科学、腫瘍、呼吸器関連の医療用医薬品を提供。中国ブラジル、インド、ロシアなどの新興諸国を含む100カ国超で事業を展開。主要製品は乳がん治療薬、高コレステロ―ル症治療薬、抗精神病薬、喘息治療薬、心不全治療薬、前立腺がん治療薬、高血圧・狭心症治療薬など。本社はロンドン。  
本社所在地 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA GBR
代表者氏名 Pascal Soriot
代表者役職名 Executive Director and Chief Executive Officer
電話番号 +44 20-7304-5000
設立年月日 33756
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 64400人
url www.astrazeneca.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 7777.00000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 105410.40000
売上高 (百万ドル) 22090.00000
企業価値(EV) (百万ドル) 118843.40000
当期純利益 (百万ドル) 2155.00000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 AstraZeneca plc (ADR) revenues decreased 2% to $22.09B. Net income before extraordinary items decreased 10% to $2.16B. Revenues reflect United Kingdom segment decrease of 26% to $2.39B Sweden segment decrease of 43% to $477M Japan segment decrease of 10% to $1.95B. Net income also reflects The Americas segment loss totaling $757M vs. income of $1.24B Other Asia.

 AZNのテクニカル分析


 AZNのニュース

   Merck & Company – Consensus Indicates Potential 8.1% Upside  2022/05/06 12:00:35 DirectorsTalk
Merck & Company with ticker code (MRK) now have 24 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 115 and 76 with a mean TP of 95.73. Given that the stocks previous close was at 88.52 this indicates there is a potential upside of 8.1%. There is a 50 day moving average of 81.96 and the 200 day MA is 79.11. The market capitalisation for the company is $222,520m. Company Website: https://www.merck.com [stock_market_widget type="chart" template="basic" color="green" assets="MRK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $240,644m based on the market concensus. Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
   Felodipine Sustained-Release Tablet Market Expected to Develop by 2028 with COVID-19 Analysis | Sandoz, Astrazeneca  2022/05/06 09:04:19 OpenPR
This unique Felodipine Sustained-Release Tablet market research study also presents important data about COVID-19 and its effects on different industries. It further explains how industries are trying to come out of this pandemic condition to set their business in
   AstraZeneca COVID booster shot effective against severe disease, finds UK study  2022/05/06 07:14:04 Express Pharma
The researchers from the UK Health Security Agency, London, estimated vaccine effectiveness by analysing data on all adults aged 18 years and above who were vaccinated with the AstraZeneca primary vaccine and either the same or the Pfizer booster vaccine The post AstraZeneca COVID booster shot effective against severe disease, finds UK study appeared first on Express Pharma .
   FDA Restricts J&J''s COVID-19 Vaccine Over Blood Clot Risk  2022/05/05 23:59:56 Voice of America News
U.S. regulators on Thursday strictly limited who can receive Johnson & Johnson''s COVID-19 vaccine because of the ongoing risk of rare but serious blood clots. The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J''s vaccine. U.S. authorities for months have recommended that Americans get Pfizer or Moderna shots instead of J&J''s vaccine. FDA''s vaccine chief Dr. Peter Marks said the agency decided to restrict the vaccine after taking another look at the data on the risks of life-threatening blood clots and concluding that they are limited to J&J''s vaccine. "If there''s an alternative that appears to be equally effective in preventing severe outcomes from COVID-19, we''d rather see people opting for that," Marks said. "But we''ve been careful to say that — compared to no vaccine — this is still a better option." The problem occurs in the first two weeks after vaccination, he added: "So if you had the vaccine six months ago you can sleep soundly tonight knowing this isn''t an issue." The FDA authorized J&J''s shot in February 2021 for adults 18 and older.
   FDA Approval For AstraZeneca - Daiichi''s Enhertu Expands To Earlier Use In Metastatic Breast Cancer  2022/05/05 16:02:49 Benzinga
The FDA has approved AstraZeneca plc (NASDAQ: AZN ) and Daiichi Sankyo''s (OTC: DSKYF ) Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast cancer. The approval covers patients who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant … Full story available on Benzinga.com
   Taiwan thanks Lithuania for pledge to donate vaccines  2021/06/27 11:56:44 Taipei Times
The government and legislators across party lines expressed their appreciation after the Lithuanian government pledged to donate 20,000 doses of the AstraZeneca COVID-19 vaccine to Taiwan. Lithuanian
   Zu wenig Nachfrage: Memmingen beendet Corona-Sonderimpfaktion mit AstraZeneca  2021/06/27 11:28:46 Nachrichten im Allgäu
180 Personen haben ein unkompliziertes Impfangebot bei der Sonderaktion im Impfzentrum Memmingen an diesem Wochenende in Anspruch genommen. Die Menschen konnten rund um die Uhr ohne Termin ins Impfzentrum kommen und erhielten eine Erstimpfung mit AstraZeneca. "Jede Impfung zählt und ist kostbar", bewertet Oberbürgermeister Manfred Schilder die Aktion rückblickend. Zu wenig Interesse an der Sonderimpfaktion"Natürlich bedaure ich, dass unser Angebot nicht von mehr Menschen angenommen wurde. Aber
   Taiwans UBI to seek usage approval for COVID vaccine candidate  2021/06/27 11:09:43 Financial Post
TAIPEI Taiwans UBI Pharma said on Sunday it would seek an emergency use authorisation (EUA) for its COVID-19 vaccine candidate after trials showed it was safe and effective. Developing its own vaccine has been a major goal of Taiwans government, although it has also ordered some 20 million shots from Moderna, AstraZeneca and the []
   AstraZeneca, Pfizer vaccines effective against Delta COVID-19 variants-study - bdnews24.com  2021/06/27 10:20:23 Bdnews24
COVID-19 vaccines made by AstraZeneca and the Pfizer-BioNTech alliance remain broadly effective against Delta and Kappa variants of the COVID-19 causing virus, which were first identified in India, ac
   Most COVAX Vaccine Recipients Excluded From New EU COVID Green Pass Thanks to Unapproved AstraZeneca Jab  2021/06/27 10:00:56 Lusaka Times
The much-trumpeted European Union COVID Digital Green Pass, which launches 1 July and is meant to vastly ease travel to Europe for vaccinated and recovered passengers is being rolled out with one important hitch. Anyone vaccinated with an AstraZeneca vaccine produced by the Serum Institute of India would not be qualified to get the pass []
   AstraZeneca says working with governments to boost COVAX donations  2021/06/02 10:41:53 Reuters
AstraZeneca (AZN.L) CEO Pascal Soriot on Wednesday said the firm was working with the COVAX vaccine-sharing mechanism and governments to boost COVID-19 vaccine supplies to the scheme, including through donations of doses.
   Japan's ruling party to recommend sending some AstraZeneca doses to Taiwan  2021/06/02 12:52:46 CNBC
Japan's ruling party to recommend sending some of its AstraZeneca Covid vaccine supply to Taiwan CNBC
   U.K. seeks additional AstraZeneca jabs against ‘beta’ COVID-19 variant - Reuters  2021/06/02 12:05:51 Seeking Alpha
   Ministro da Saúde comemora transferência de tecnologia da vacina da AstraZeneca  2021/06/01 22:06:42 Forbes Brasil
Marcelo Queiroga também anunciou acordo para 50 milhões de doses do imunizante a serem produzidos pela Fiocruz […] O post Ministro da Saúde comemora transferência de tecnologia da vacina da AstraZeneca apareceu primeiro em Forbes Brasil .
   'No change to two-dose schedule for Covishield'  2021/06/01 11:59:40 Economic Times India
India will stick to its schedule of giving two doses of AstraZeneca's vaccine, a senior government adviser said on Tuesday. "India's Covishield schedule is of two doses… there is no change and Covaxin is also for two doses," government advisor V K Paul told reporters at a news conference. Mixing of vaccines is not a protocol and research is currently being conducted on this, he added.

 関連キーワード  (医薬品 米国株 アストラゼネカ AZN )

 twitter  (公式ツイッターやCEOツイッターなど)

AZN動画